Immune reconstitution inflammatory syndrome

Summary

Immune reconstitution inflammatory syndrome (MONDO:0100185) is a disease and 13 clinical trials. Top therapeutic interventions include prednisolone, methylprednisolone, and naproxen. A subtype of immune system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 13

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	immune reconstitution inflammatory syndrome
Mondo ID	MONDO:0100185
MeSH	D054019
ICD-10-CM	D89.3
ICD-11	180703474
NCIT	C125712
UMLS	C1619738
MedGen	295297
Is cancer (heuristic)	no

Also known as: immune reconstitution inflammatory syndrome associated with Kaposi sarcoma · immune reconstitution syndrome · immune restoration disease · IRD · IRIS · IRS

Disease family

This is a subtype of immune system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › immune reconstitution inflammatory syndrome

Related subtypes (46): hypersensitivity reaction disease, immune system cancer, immune system organ benign neoplasm, bone marrow disorder, thymus gland disorder, inborn error of immunity, leukocyte disorder, psoriasis, spondyloarthropathy, aggressive insulitis, benign insulitis, inflammatory bowel disease, autoimmune disease, TNF receptor 1-associated periodic fever syndrome, epidermodysplasia verruciformis, Vici syndrome, proteosome-associated autoinflammatory syndrome, hyperimmunoglobulinemia D with periodic fever, transcobalamin II deficiency, pyogenic arthritis-pyoderma gangrenosum-acne syndrome, granulomatosis with polyangiitis, autosomal recessive osteopetrosis 7, graft versus host disease, congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome, Roifman syndrome, cryopyrin-associated periodic syndrome, anti-HLA hyperimmunization, acquired immunodeficiency, erythroderma desquamativum, autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis, familial Mediterranean fever, 22q11.2 deletion syndrome, T-cell large granular lymphocyte leukemia, twin to twin transfusion syndrome, immunodeficiency disease, immunoproliferative disorder, cytokine receptor deficiency, immunodeficiency-related disorder, phagocytic cell dysfunction, thrombocytopenic purpura, lymphoid system disorder, growth hormone insensitivity with immune dysregulation 1, autosomal recessive, cytokine release syndrome, early-onset autoimmunity-autoinflammation-immunodeficiency syndrome, CADINS disease, autoinflammation, panniculitis, and dermatosis syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 13.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE3	2
PHASE4	1
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01211665	PHASE4	TERMINATED	Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)
NCT01442428	PHASE2/PHASE3	WITHDRAWN	Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial
NCT01924286	PHASE3	COMPLETED	Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone
NCT03092817	PHASE3	COMPLETED	Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
NCT03296553	PHASE2	COMPLETED	Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
NCT02147405	Not specified	RECRUITING	PET Imaging and Lymph Node Assessment of IRIS in People With AIDS
NCT07565623	Not specified	NOT_YET_RECRUITING	Prevention of AIDS With Opportunistic Infection Paradoxical IRIS
NCT00286767	Not specified	COMPLETED	Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral Therapy
NCT00988780	Not specified	UNKNOWN	Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients
NCT01240486	Not specified	COMPLETED	IMPAACT P1073: Study of IRIS for Infants and Children Initiating HAART at Int’l Sites
NCT01557803	Not specified	COMPLETED	Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome
NCT02063880	Not specified	COMPLETED	Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)
NCT05484050	Not specified	UNKNOWN	VEGF in Iris Tissue in Primary Congenital Glaucoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PREDNISOLONE	4	2
METHYLPREDNISOLONE	4	1
NAPROXEN	4	1
VALGANCICLOVIR	4	1
CHEMBL1618254	0	1